Welcome to MenoGeniX, Inc.
MenoGeniX is a clinical stage biotechnology company focused on developing a drug to treat hot flashes and other menopausal symptoms. Hot flashes and related symptoms represent a significant unmet healthcare need in the United States, not only in naturally occurring menopausal women, but also for women who experience surgically induced menopause. The only two currently approved medications for hot flashes and menopausal symptoms are hormone therapy (HT) with estrogens which is associated with significant health risks including cardiovascular disease and breast cancer. The other recently approved therapy is Brisdelle, a low-dose form of the anti-depressant paroxetine which also has serious side effects. The overall goal of MenoGeniX is to confirm preliminary observations from its Phase Ib proof-of-concept clinical trial that the use of its experimental treatment can significantly reduce the number and amplitude of hot flash episodes and related symptoms. It is expected that this treatment will provide a safer alternative to the currently approved therapies available to women undergoing the menopause transition. Further drug development plans for Phase II clinical trials and regulatory approval are underway.